GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » COGS-to-Revenue

Venus Medtech (Hangzhou) (HKSE:02500) COGS-to-Revenue : 0.20 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) COGS-to-Revenue?

Venus Medtech (Hangzhou)'s Cost of Goods Sold for the six months ended in Dec. 2023 was HK$52.3 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$257.9 Mil.

Venus Medtech (Hangzhou)'s COGS to Revenue for the six months ended in Dec. 2023 was 0.20.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Venus Medtech (Hangzhou)'s Gross Margin % for the six months ended in Dec. 2023 was 79.72%.

Venus Medtech (Hangzhou) COGS-to-Revenue Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) COGS-to-Revenue Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial 0.17 0.18 0.22 0.23 0.21

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.22 0.24 0.21 0.20

Venus Medtech (Hangzhou) COGS-to-Revenue Calculation

Venus Medtech (Hangzhou)'s COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=111.749 / 537.453
=0.21

Venus Medtech (Hangzhou)'s COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=52.291 / 257.873
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Medtech (Hangzhou)  (HKSE:02500) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Venus Medtech (Hangzhou)'s Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 52.291 / 257.873
=79.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Venus Medtech (Hangzhou) COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:02235 HKSE:01696 HKSE:06118 HKSE:06609 HKSE:02170 HKSE:02297 HKSE:02190 HKSE:02216 HKSE:02393 HKSE:01612 ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
VMTHF:USA
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Website
https://www.venusmedtech.com
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines